Yun-long Li, a creative chemist who was committed to bringing innovative medicines to cancer patients. The authors would like to thank Xiaoming Wen, Sybil Liensinine Perchlorate OConnor, and Margaret Favata for technical assistance, and Xin He and Yanlong Li for selectivity screening. This study was sponsored by Incyte Corporation (Wilmington, Delaware). mouse plasma. (DOCX) pone.0199108.s007.docx (18K) GUID:?60887891-6D1D-4804-9EC2-1AF2888A96B3 S4 File: Original Western blot images. (DOCX) pone.0199108.s008.docx (2.9M) GUID:?01ED311B-A5E5-49B6-91BF-B6153BBAA910 Data Availability StatementAll relevant data are within the paper and its Supporting Information files. Abstract The Proviral Integration site of Moloney murine leukemia virus (PIM) serine/threonine protein kinases are overexpressed in many hematologic and solid tumor malignancies and play central roles in intracellular signaling networks important in tumorigenesis, including the Janus kinaseCsignal Liensinine Perchlorate transducer and activator of transcription (JAK/STAT) and phosphatidylinositol 3-kinase (PI3K)/AKT pathways. The three PIM kinase isozymes (PIM1, PIM2, and PIM3) share similar downstream substrates with other key oncogenic kinases Liensinine Perchlorate and have differing but mutually compensatory functions across tumors. This supports the therapeutic potential of pan-PIM kinase inhibitors, especially in combination with other anticancer agents chosen based on their role in overlapping signaling networks. Reported here is a preclinical characterization of INCB053914, a novel, potent, and selective adenosine triphosphate-competitive pan-PIM kinase inhibitor. and in blood samples from patients receiving INCB053914 in an ongoing phase 1 dose-escalation study. gene expression has been ablated remain viable and fertile, unlike phenotypes resulting from other gene deletions, which are typically embryonically lethal (eg, and kinase inhibition) by INCB053914 was determined by incubating 106 MOLM-16 (AML), Pfeiffer (DLBCL), KMS-12-PE (MM), and KMS-12-BM (MM) cells with INCB053914 at concentrations ranging from 0 (phosphate-buffered saline [PBS]) to 1 1 M for 2 hours in Roswell Park Memorial Institute (RPMI) medium. Cells were centrifuged at 1,000 rpm for 10 minutes and lysed with 1 lysis buffer (Cell Signaling Technology, Danvers, Massachusetts) supplemented with 1 mM phenylmethane sulfonyl fluoride (Sigma-Aldrich, St Louis, Missouri) and proteinase inhibitor cocktail (CalBiochem, San Diego, California). Cell lysates were stored at C80C before determining phosphoprotein and PIM2 levels by Western blotting using anti-pBAD (S112), anti-p4E-BP1 (S65), pp70S6K (T389), pS6 (S285/S286), and anti-PIM2 antibodies (Cell Signaling Technology). Rabbit polyclonal to FOXO1A.This gene belongs to the forkhead family of transcription factors which are characterized by a distinct forkhead domain.The specific function of this gene has not yet been determined; The effect of INCB053914 on the level of pBAD was further investigated in KMS-12-BM and MOLM-16 cells, which were suspended in RPMI + 10% fetal bovine serum (FBS) and seeded into 96-well v-bottom polypropylene plates (Greiner, Munroe, North Carolina; 4 105 cells/well/100 l) in the presence of 5 l INCB053914 at a final concentration range of 0.1 nM to 1 1,000 nM. After 2.5 hours at 37C and 5% CO2, the cells were lysed in 100 l of cell extraction buffer (Cell Signaling Technology) containing phenylmethane sulfonyl fluoride, HaltTM phosphatase, and protease inhibitors (Thermo Fisher Scientific, Waltham, Massachusetts; Calbiochem). The concentration of pBAD protein in the cell lysates was quantified using a Human pBAD S112 ELISA Kit (Cell Signaling Technology). The effects of INCB053914 on pBAD, pp70S6K, and p4E-BP1 levels and on the expression of PIM isozymes also were assessed in primary bone marrow blasts (Stem Cell and Xenograft Core, University of Pennsylvania, Philadelphia, Pennsylvania) or in peripheral blood mononuclear cells (PBMCs) derived from whole blood samples obtained with informed written consent from adult patients with AML enrolled in an ongoing phase 1/2 dose-escalation trial, which was conducted in accordance with the study protocol approved by the respective institutional review boards or independent ethics committees. Only samples initially containing >90% viable cells were used (assessed by Trypan Blue staining). Immediately after thawing, the blasts were cultured in RPMI + 10% FBS with INCB053914 for 2 hours at 37C, before lysis. For determinations of PIM2 expression in PBMCs, whole blood samples were treated overnight with increasing concentrations of INCB053914; total PBMCs were isolated by Ficoll-Paque density gradient centrifugation before lysis. The levels of PIM isozymes and phosphoproteins in cell lysates were detected by Western blotting using the same primary antibodies as above. Erythroid colony formation assays were performed using primary cultures obtained from peripheral blood samples from patients with JAK2 V216F MPNs, as previously described . Samples were obtained with informed written consent from adult patients through the Moffitt Cancer Center Total Cancer Care protocol (MCC 14690/ Liberty IRB #12.11.0023) approved Liensinine Perchlorate by the Moffitt Cancer Center Scientific Review Committee. studies Non- GLP Liensinine Perchlorate studies intended to characterize the pharmacology of INCB053914 were conducted in accordance with Incyte Corporation’s Animal Use Protocols and DuPont Stine-Haskell SOPs. Animals were housed in barrier facilities fully accredited by the Association.